Abstract: A data processing method includes: displaying a document source control in a target application; displaying a to-be-authorized-document list in response to a trigger operation on the document source control, the to-be-authorized-document list including one or more document titles, the one or more document titles including a title that is in a document application and that corresponds to document data associated with a first object, and the first object being logged in to the document application through the target application; and displaying a first authorized-document list including a first title in response to a trigger operation on the to-be-authorized-document list (S103), the first title being a triggered document title, and the target application having a permission to perform service processing on document data corresponding to the first title.

Abstract: An information handling system includes first and second graphics processing units, and a processor. The first graphics processing unit includes first, second, and third display ports. The second graphics processing unit includes fourth, fifth, and sixth display ports. The processor receive a buffer request that identifies a number of frame buffers to be created. The processor call a graphics multiple buffer render create buffer command to divide a graphics multiple buffer render buffer into multiple buffers. The multiple buffers of the graphics multiple buffer render buffer are based on the number of frame buffers identified in the buffer request. The processor create multiple frame buffers. The number of the frame buffers is the same as a number of the buffers of the graphics multiple buffer render buffer. Each of the frame buffers provide data to a different one of the first, second, third, fourth, fifth, and sixth display ports.

Abstract: The invention relates to an anti-coronavirus polypeptide as well as derivatives and application thereof, provides the anti-coronavirus polypeptide, and provides cholesterol-containing derivatives of the polypeptide on the basis of the anti-coronavirus polypeptide. Particularly, the original strain and the variant strain of the SARS-COV-2 have an unexpected inhibition effect, can be used for preparing medicines or vaccines for preventing or treating the new coronavirus, and have great prevention or treatment potential.

Abstract: Provided in the present disclosure is an antibody or an antigen-binding fragment thereof that binds to the respiratory syncytial virus F protein. Further provided in the present disclosure is the use of the antibody or the antigen-binding fragment thereof in the preparation of a drug for the treatment and/or prevention of RSV infections.

Abstract: The present application relates to a polypeptide for preventing or treating a novel coronavirus and an application thereof. The polypeptide is P3 polypeptide and any one of P3-1 polypeptide, P3-2 polypeptide, P3-3 polypeptide, P3-4 polypeptide, and P3-5 polypeptide derived from the P3 polypeptide. The amino acid sequences of the P3 polypeptide, the P3-1 polypeptide, the P3-2 polypeptide, the P3-3 polypeptide, the P3-4 polypeptide, and the P3-5 polypeptide are respectively shown in SEQ ID NOs: 1-6. The polypeptide of the present application has a strong inhibitory effect on original strains and a plurality of variant strains of the novel coronavirus, and can be used for preparing a drug or a vaccine for preventing and/or treating diseases caused by the novel coronavirus. The polypeptide is expected to also have the potential of preventing and/or treating new variant strains appearing in the future and sarbecovirus.

Abstract: Provided in the present disclosure are a Zika/dengue vaccine and its application thereof. The present disclosure introduces a mutation into the E-protein FL fusion region of the Zika virus or dengue virus. Antigens with said mutations are unable to bind to antibodies that causes ADE. After immunization with the vaccine of the present disclosure acquired from the said antigens, production of FL epitope-induced antibodies can be prevented, thereby reducing or eliminating the ADE effect.

Abstract: The present disclosure provides two specific T cell receptors targeting a G12V or G12C mutant epitope of a KRAS gene, and an anti-tumor use thereof. Each of the two T cell receptors consists of an ? peptide chain and a ? peptide chain. Further provided are an antigen binding fragment of the T cell receptors, a nucleic acid encoding the T cell receptors or an antigen binding fragment thereof, a vector comprising the nucleic acid, and a host cell comprising the vector. Further provided is a method for preparing a specific T cell receptor for a KRAS G12V mutation or an antigen-binding fragment thereof. The specific T cell receptor and antigen-binding fragment thereof can be used as an immune activator to stimulate an immune response of an organism, thereby generating an effect against tumors and other diseases.

Abstract: Provided in the present invention are a humanized monoclonal antibody for the 2019 novel coronavirus (2019-nCOV) and the use thereof. The antibody is capable of specifically binding with a receptor binding domain (RBD) of 2019-nCOV and blocking the binding between the RBD of 2019-nCOV and ACE2, and furthermore inhibiting the infection caused by 2019-nCOV.

Abstract: The embodiments of the present disclosure relate to antigens of ?-coronaviruses, preparation methods and uses thereof. The amino acid sequence of the antigen of the ?-coronavirus includes an amino acid sequence arranged in a (A-B)-(A-B) pattern or an amino acid sequence arranged in a (A-B)-C-(A-B) pattern or an amino acid sequence arranged in a (A-B)-(A-B?) pattern or an amino acid sequence arranged in a (A-B)-C-(A-B?) pattern. The antigen of the ?-coronavirus has a single-chain dimer structure. A single-chain dirtier expressed according to examples of the present disclosure is stable in content and has excellent immunogenicity as an antigen of a ?-coronavirus, and a vaccine prepared by using the single-chain dimer as an antigen of a ?-coronavirus can elicit high-titer neutralizing antibodies in mice.

Abstract: Disclosed is a virus inhibiting Wnt signaling and a method for Wnt signaling using the virus. Also disclosed is a method for treating tumors using the virus.

Abstract: A document editing method includes: displaying a shared document page including content of a target shared document and description information of document insertion content. The target shared document and the document insertion content are from different content platforms. The method includes displaying a link editing page of the document insertion content in response to an editing operation on the description information of the document insertion content; acquiring target link address information edited through the link editing page; and updating the document insertion content to target content corresponding to the target link address information.

Abstract: The embodiments of the present disclosure relate to antigens of ?-coronaviruses, preparation methods and uses thereof. The amino acid sequence of the antigen of the ?-coronavirus includes an amino acid sequence arranged in a (A-B)-(A-B) pattern or an amino acid sequence arranged in a (A-B)-C-(A-B) pattern or an amino acid sequence arranged in a (A-B)-(A-B?) pattern or an amino acid sequence arranged in a (A-B)-C-(A-B?) pattern. The antigen of the ?-coronavirus has a single-chain dimer structure. A single-chain dirtier expressed according to examples of the present disclosure is stable in content and has excellent immunogenicity as an antigen of a ?-coronavirus, and a vaccine prepared by using the single-chain dimer as an antigen of a ?-coronavirus can elicit high-titer neutralizing antibodies in mice.

Abstract: The invention relates to a process for inhibiting the infection of influenza viruses and a polypeptide or protein medicine used therein. More particularly, the invention involves a process for inhibiting the highly pathogenic avian influenza virus (such as H5N1 subtype) infection and human influenza virus (such as H1N1 subtype and H3N2 subtype) infection, as well as the polypeptide or protein involved therein, and a polynucleotide encoding the polypeptide or protein and a vector or host cell expressing said polypeptide or protein.

Abstract: The invention relates to a process for inhibiting the infection of influenza viruses and a polypeptide or protein medicine used therein. More particularly, the invention involves a process for inhibiting the highly pathogenic avian influenza virus (such as H5N1 subtype) infection and human influenza virus (such as H1N1 subtype and H3N2 subtype) infection, as well as the polypeptide or protein involved therein, and a polynucleotide encoding the polypeptide or protein and a vector or host cell expressing said polypeptide or protein.

Abstract: The present invention relates to a recombinant soluble T cell receptor. The T cell receptor (TCR) is refolded and comprises a recombinant TCR &agr; or &ggr; chain extracellular domain having a first heterologous C-terminal dimerisation peptide; and a recombinant TCR &bgr; or &dgr; chain extracellular domain having a second C-terminal dimerisation peptide which is specifically heterodimerised with the first dimerisation peptide to form a heterodimerisation domain, which may be a coiled coil domain. The invention also provides nucleic acid sequences encoding the recombinant TCR and a method for producing the recombinant TCR.